blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2363471

EP2363471 - IMMUNOASSAY METHOD FOR HUMAN CXCL1 PROTEIN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.08.2017
Database last updated on 22.01.2025
Most recent event   Tooltip20.07.2018Lapse of the patent in a contracting state
New state(s): MT		published on 22.08.2018  [2018/34]
Applicant(s)For all designated states
Toray Industries, Inc.
1-1, Nihonbashi-Muromachi 2-chome Chuo-ku
Tokyo, 103-8666 / JP
[2011/36]
Inventor(s)01 / KANAMORI Satoko
c/o Basic Research Laboratories
Toray Industries Inc.
10-1, Tebiro 6-chome
Kamakura-shi Kanagawa 248-8555 / JP
02 / JUNG Giman
c/o Basic Research Laboratories
Toray Industries Inc.
10-1, Tebiro 6-chome
Kamakura-shi Kanagawa 248-8555 / JP
03 / TANAKA Yoshinori
c/o Basic Research Laboratories
Toray Industries Inc.
10-1, Tebiro 6-chome
Kamakura-shi Kanagawa 248-8555 / JP
04 / TAKAYAMA Aiko
c/o Basic Research Laboratories
Toray Industries Inc.
10-1, Tebiro 6-chome
Kamakura-shi Kanagawa 248-8555 / JP
 [2011/36]
Representative(s)Prüfer & Partner mbB Patentanwälte · Rechtsanwälte
Sohnckestraße 12
81479 München / DE
[2016/41]
Former [2011/36]Prüfer & Partner GbR European Patent Attorneys
Sohnckestraße 12
81479 München / DE
Application number, filing date09823664.929.10.2009
[2016/41]
WO2009JP68587
Priority number, dateJP2008028190831.10.2008         Original published format: JP 2008281908
JP2009003941123.02.2009         Original published format: JP 2009039411
[2011/36]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010050554
Date:06.05.2010
Language:JA
[2010/18]
Type: A1 Application with search report 
No.:EP2363471
Date:07.09.2011
Language:EN
[2011/36]
Type: B1 Patent specification 
No.:EP2363471
Date:12.10.2016
Language:EN
[2016/41]
Search report(s)International search report - published on:JP06.05.2010
(Supplementary) European search report - dispatched on:EP01.10.2013
ClassificationIPC:C12N15/09, C07K16/18, C12P21/08, G01N33/53, // C07K16/24, G01N33/68
[2013/44]
CPC:
C07K16/24 (EP,KR,US); G01N33/6863 (EP,KR,US); G01N33/53 (KR);
G01N33/543 (KR,US); G01N33/6857 (KR,US); A61K2039/505 (EP,KR,US);
C07K2317/34 (EP,KR,US); C07K2317/565 (KR,US); C07K2317/76 (EP,KR,US);
G01N2333/522 (KR,US) (-)
Former IPC [2011/36]C12N15/09, C07K16/18, C12P21/08, G01N33/53
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2016/41]
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:IMMUNOASSAYVERFAHREN FÜR MENSCHLICHES CXCL1-PROTEIN[2011/36]
English:IMMUNOASSAY METHOD FOR HUMAN CXCL1 PROTEIN[2011/36]
French:PROCÉDÉ D'IMMUNOESSAI POUR LA PROTÉINE CXCL1 HUMAINE[2011/36]
Entry into regional phase24.05.2011Translation filed 
24.05.2011National basic fee paid 
24.05.2011Search fee paid 
24.05.2011Designation fee(s) paid 
24.05.2011Examination fee paid 
Examination procedure24.05.2011Examination requested  [2011/36]
24.04.2014Amendment by applicant (claims and/or description)
05.10.2015Despatch of a communication from the examining division (Time limit: M04)
12.01.2016Reply to a communication from the examining division
29.04.2016Communication of intention to grant the patent
05.09.2016Fee for grant paid
05.09.2016Fee for publishing/printing paid
05.09.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.10.2015
Opposition(s)13.07.2017No opposition filed within time limit [2017/38]
Fees paidRenewal fee
27.10.2011Renewal fee patent year 03
30.10.2012Renewal fee patent year 04
31.10.2013Renewal fee patent year 05
31.10.2014Renewal fee patent year 06
28.10.2015Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.10.2009
AT12.10.2016
BE12.10.2016
CY12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
MK12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
SE12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
TR12.10.2016
IE29.10.2016
LU29.10.2016
CH31.10.2016
LI31.10.2016
MT31.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
[2018/33]
Former [2018/29]HU29.10.2009
AT12.10.2016
BE12.10.2016
CY12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
MK12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
SE12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
TR12.10.2016
IE29.10.2016
LU29.10.2016
CH31.10.2016
LI31.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2018/28]HU29.10.2009
AT12.10.2016
BE12.10.2016
CY12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
MK12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
SE12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
IE29.10.2016
LU29.10.2016
CH31.10.2016
LI31.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/51]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
SE12.10.2016
SI12.10.2016
SK12.10.2016
SM12.10.2016
IE29.10.2016
LU29.10.2016
CH31.10.2016
LI31.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/41]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
SE12.10.2016
SK12.10.2016
SM12.10.2016
LU29.10.2016
CH31.10.2016
LI31.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/38]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
SE12.10.2016
SK12.10.2016
SM12.10.2016
CH31.10.2016
LI31.10.2016
BG12.01.2017
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/37]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
IT12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
SE12.10.2016
SK12.10.2016
SM12.10.2016
CH31.10.2016
LI31.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/36]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
SE12.10.2016
SK12.10.2016
CH31.10.2016
LI31.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/35]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
EE12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
PL12.10.2016
RO12.10.2016
SE12.10.2016
CH31.10.2016
LI31.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/34]AT12.10.2016
BE12.10.2016
CZ12.10.2016
DK12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
PL12.10.2016
SE12.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/33]AT12.10.2016
BE12.10.2016
DK12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
MC12.10.2016
NL12.10.2016
PL12.10.2016
SE12.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/26]AT12.10.2016
BE12.10.2016
ES12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
PL12.10.2016
SE12.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
PT13.02.2017
Former [2017/23]AT12.10.2016
BE12.10.2016
FI12.10.2016
HR12.10.2016
LT12.10.2016
LV12.10.2016
NL12.10.2016
PL12.10.2016
SE12.10.2016
NO12.01.2017
GR13.01.2017
IS12.02.2017
Former [2017/12]LV12.10.2016
BE31.10.2016
Documents cited:Search[I]EP1930445  (TORAY INDUSTRIES [JP]; UNIV KYOTO [JP]) [I] 1-15 * paragraph [0111] * * paragraph [0074] - paragraph [0076] * * paragraph [0087] *;
 [Y]US2008206766  (MACOSKA JILL A [US]) [Y] 1-15 * paragraph [0189] *;
 [Y]CN101290318  (SHANGHAI CANCER INST [CN] SHANGHAI CANCER INST) [Y] 1-15 * claims 1-10 *
 [Y]  - HIROAKI KAWANISHI ET AL, "Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 9, doi:10.1158/1078-0432.CCR-07-1922, ISSN 1078-0432, (20080501), pages 2579 - 2587, (20080501), XP008149803 [Y] 1-15 * page 2581 *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-07-1922
International search[Y]WO2007026895  (TORAY INDUSTRIES [JP], et al);
 [Y]WO2008013257  (SHIONOGI & CO [JP], et al)
 [Y]  - KAWANISHI H. ET AL., "Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.", CLIN. CANCER. RES., (200805), vol. 14, no. 9, pages 2579 - 2587, XP008149803

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-07-1922
 [Y]  - WEN Y. ET AL., "GROalpha is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1.", CLIN. CANCER. RES., (2006), vol. 12, no. 20, pages 5951 - 5959, XP008149807

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-06-0736
 [Y]  - YANG G. ET AL., "The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.", PROC. NATL. ACAD. SCI. USA., (2006), vol. 103, no. 44, pages 16472 - 16477, XP008149819

DOI:   http://dx.doi.org/10.1073/pnas.0605752103
by applicantWO2007026895
 US5714350
 US6350861
 WO9713844
 WO9002809
 JPH1054830
    - HIROAKI KAWANISHI ET AL., CLINICAL CANCER RESEARCH, (2008), vol. 14, no. 9, pages 2579 - 2587
    - GONG YANG ET AL., PNAS, (2006), vol. 103, no. 44, pages 16472 - 16477
    - YU WEN ET AL., CLINICAL CANCER RESEARCH, (2006), vol. 12, no. 20, pages 5951 - 5959
    - JING LUAN ET AL., JOURNAL OF LEUKOCYTE BIOLOGY, (1997), vol. 62, no. 5, pages 588 - 597
    - E. A. KABAT ET AL., Sequences of proteins of immunological interest, NIH PUBLICATION, (1991), vol. 1
    - NATURE, (1986), vol. 321, page 522
    - HOLLIGER ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1993), vol. 90, pages 6444 - 6448
    - MARVIN ET AL., ACTA PHARMACOL. SIN., (2005), vol. 26, pages 649 - 658
    - OLAFSEN ET AL., PROT. ENGR. DES. SEL., (2004), vol. 17, pages 21 - 27
    - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 522 - 554
    - JOURNAL OF IMMUNOLOGY, (1998), vol. 160, pages 3393 - 3402
    - PNAS, (1989), vol. 86, page 6077
    - PNAS, (1987), vol. 84, page 7413
    - VIROLOGY, (1973), vol. 52, pages 456 - 467
    - NATURE, (1977), vol. 266, pages 550 - 552
    - BRINKMANN ET AL., J IMMUNOL METHODS, (1995), vol. 182, pages 41 - 50
    - "Bovine Papilloma Virus Vector", HAJIME KARASUYAMA, Experimental Medicine Separate Volume: Genetic Engineering Handbook, YODOSHA, (1991), pages 297 - 299
    - EUROPEAN JOURNAL OF CANCER RESEARCH PREVIEW, (1996), vol. 5, pages 512 - 519
    - CANCER RESEARCH, (1990), vol. 50, pages 1495 - 1502
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.